title: The impact of biofilm-producing bacteria on chronic bacterial prostatitis treatment: results from a longitudinal cohort study.
abstract: OBJECTIVE
  We aim to evaluate the role of biofilm-producing bacteria in the clinical response to antibiotic therapy among patients affected by chronic bacterial prostatitis (CBP).
  
  
  METHODS
  All patients attending our centre from January to December 2008 due to prostatitis-like symptoms with a positive Meares-Stamey test were enroled. The clinical symptoms were assessed according to the NIH-CPSI, and the bacterial strains isolated from the patients enroled were identified and tested for antibiotic sensitivity using cards of the Vitek II semi-automated System for Microbiology (BioMerieux). Quantitative bacterial slime production was assessed by the Christensen microwell assay. All patients were treated with fluoroquinolones for 4 weeks and reevaluated clinically and microbiologically after 3 months.
  
  
  RESULTS
  One hundred and sixteen patients were enroled, and 150 bacterial strains were isolated from all patients. About 85 % of these strains were strong or moderate biofilm producers. Patients with strong or moderate biofilm-producing bacteria had a higher NIH-CPSI symptom score than those without biofilm-producing bacteria (mean 17.6 ± 5.6 vs. 14.1 ± 3.3; p = 0.0009). At the follow-up, 68 patients (58.6 %) had negative microbiological tests, but only 11 (9.48 %) reported a reduction in NIH-CPSI score. Improvement of symptoms was found statistically significantly less frequent in patients with biofilm-producing bacteria than in those without (p = 0.03). Ultrastructural analysis showed cellular forms in active replication with aberrant morphology of unknown cause and confirmed strong slime production with consistent bacterial stratification.
  
  
  CONCLUSIONS
  In our CBP population, biofilm-producing bacteria were commonly found and had a significant negative impact on the clinical response to antibiotic therapy.
authors.affiliation: Department of Clinical Care Medicine and Surgery, Urology Unit Santa Maria Annunziata Hospital, University of Florence, Florence, Italy.
authors.forename: Riccardo
authors.initials: R
authors.lastname: Bartoletti
authors.forename: Tommaso
authors.initials: T
authors.lastname: Cai
authors.forename: Gabriella
authors.initials: G
authors.lastname: Nesi
authors.forename: Sara
authors.initials: S
authors.lastname: Albanese
authors.forename: Francesca
authors.initials: F
authors.lastname: Meacci
authors.forename: Sandra
authors.initials: S
authors.lastname: Mazzoli
authors.forename: Kurt
authors.initials: K
authors.lastname: Naber
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001419:Bacteria / Q000302:isolation & purification / Q000378:metabolism*; D018441:Biofilms / Q000254:growth & development*; D002908:Chronic Disease; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011379:Prognosis; D011472:Prostatitis / Q000188:drug therapy / Q000382:microbiology*; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents
references.citation: Expert Rev Anti Infect Ther. 2003 Aug;1(2):275-82
references.pmid: 15482123
references.citation: Arch Ital Urol Androl. 2001 Jun;73(2):105-13
references.pmid: 11758533
references.citation: BJU Int. 2000 Nov;86(8):935-41
references.pmid: 11069430
references.citation: J Urol. 1978 Aug;120(2):266
references.pmid: 671653
references.citation: Drugs. 2009;69(1):71-84
references.pmid: 19192937
references.citation: BMC Infect Dis. 2010 Mar 30;10:81
references.pmid: 20353563
references.citation: Eur Urol. 2007 May;51(5):1385-93
references.pmid: 17107749
references.citation: Eur Urol. 2005 Jun;47(6):805-11
references.pmid: 15925077
references.citation: Br J Urol. 1990 Jul;66(1):47-54
references.pmid: 2203502
references.citation: Eur Urol. 1997;31(2):129-40
references.pmid: 9076454
references.citation: JAMA. 1999 Jul 21;282(3):236-7
references.pmid: 10422990
references.citation: J Urol. 1999 Aug;162(2):369-75
references.pmid: 10411041
references.citation: Clin Infect Dis. 1992 Nov;15 Suppl 1:S216-27
references.pmid: 1477233
references.citation: J Microbiol. 2011 Jun;49(3):448-54
references.pmid: 21717331
references.citation: J Clin Microbiol. 1985 Dec;22(6):996-1006
references.pmid: 3905855
references.citation: Int J Antimicrob Agents. 2006 Aug;28 Suppl 1:S21-5
references.pmid: 16828264
references.citation: Infez Med. 2009 Jun;17 Suppl 1:10-6
references.pmid: 19696557
references.citation: J Urol. 2007 Jan;177(1):365-8
references.pmid: 17162092
references.citation: J Urol. 2000 May;163(5):1591-4
references.pmid: 10751894
references.citation: Urology. 1989 Nov;34(5):241-5
references.pmid: 2815444
references.citation: J Urol. 2007 Dec;178(6):2411-5; discussion 2415
references.pmid: 17937946
references.citation: FEMS Immunol Med Microbiol. 2010 Aug;59(3):337-44
references.pmid: 20298500
references.citation: J Urol. 2003 Sep;170(3):818-22
references.pmid: 12913707
references.citation: J Androl. 2012 Jul-Aug;33(4):615-23
references.pmid: 21979301
references.citation: Clin Microbiol Rev. 2002 Apr;15(2):167-93
references.pmid: 11932229